Pathology of non-alcoholic fatty liver disease

被引:212
|
作者
Bedossa, Pierre [1 ,2 ]
机构
[1] Beaujon Hosp, AP HP, Pathol Dept, Paris, France
[2] Univ Paris Diderot, Paris, France
关键词
fibrosis; liver biopsy; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; MORBIDLY OBESE-PATIENTS; SCORING SYSTEM; HISTOLOGIC FEATURES; FOLLOW-UP; STEATOHEPATITIS; FIBROSIS; NAFLD; PROGRESSION; BIOPSIES; STEATOSIS;
D O I
10.1111/liv.13301
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of lesions ranging from steatosis (Non-alcoholic Fatty Liver or NAFL) to a complex pattern with hepatocellular injury and inflammation (non-alcoholic steatohepatitis; NASH) in the absence of alcohol intake. However, it is increasingly clear that intermediate patterns may exist. The histopathological evaluation of liver biopsy samples is central in the diagnosis of NAFLD and NASH in the absence of sufficiently accurate non-invasive tests because a precise definition of each group is a key issue. When at least 5% of hepatocytes display steatosis, patients can be defined as having NAFLD in an appropriate clinical context. When, in addition, lobular inflammation and liver cell clarification/ballooning are present, then the lesion is usually defined as NASH. Evaluation of the stage of fibrosis is even more fundamental than necroinflammation since it is the main prognostic factor of this disease. Semi-quantitative histological scoring systems have been proposed for NAFLD, but they are not useful in clinical practice and each has certain limitations. For comprehensive purposes, we suggest describing histopathological lesions in NAFLD using the SAF (Steatosis, Activity, Fibrosis) score which assesses separately the grade of steatosis (5, from SO to 53), the grade of activity (A from AO to A4 by adding grades of ballooning and lobular inflammation, both from 0 to 2) and the stage of fibrosis (F from FO to F4).
引用
收藏
页码:85 / 89
页数:5
相关论文
共 50 条
  • [31] PTEN in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis and Cancer
    Peyrou, Marion
    Bourgoin, Lucie
    Foti, Michelangelo
    [J]. DIGESTIVE DISEASES, 2010, 28 (01) : 236 - 246
  • [32] Non-alcoholic fatty liver disease and liver secretome
    Muhammad Sohaib Khan
    Choongho Lee
    Sang Geon Kim
    [J]. Archives of Pharmacal Research, 2022, 45 : 938 - 963
  • [33] Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tomiya, Tomoaki
    [J]. HEPATOLOGY RESEARCH, 2010, 40 (01) : 108 - 110
  • [34] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Sila Cocciolillo
    Giustino Parruti
    Leonardo Marzio
    [J]. World Journal of Hepatology, 2014, (07) : 496 - 503
  • [35] Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Pittaras, Andreas
    Faselis, Charles
    Narayan, Puneet
    Kokkinos, Peter
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 239 - 245
  • [36] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
    Keller, KM
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869
  • [37] Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
    Wu, Dongqing
    Zhu, Huaqing
    Wang, Hua
    [J]. FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [38] Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
    Weiner, R. A.
    [J]. DIGESTIVE DISEASES, 2010, 28 (01) : 274 - 279
  • [39] An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (08) : 759 - 772
  • [40] Glycosyltransferases and non-alcoholic fatty liver disease
    Yu-Tao Zhan
    Hai-Ying Su
    Wei An
    [J]. World Journal of Gastroenterology, 2016, (08) : 2483 - 2493